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Abstract
Background: Confirmatory factor analysis (CFA) of Diagnostic and Statistical
Manual of Mental Disorders (Fourth Edition) (DSM-IV) three-factor posttrau-
matic stress disorder (PTSD) diagnostic criteria was conducted to determine fit
for this patient population. An exploratory factor analysis (EFA) of alternate
symptom structures was planned to identify symptoms that cluster in this
population. The response of symptom factors to treatment with venlafaxine
extended release (ER) was explored. Methods: Baseline 17-item Clinician-
Administered PTSD Scale (CAPS-SX17) data were pooled from patients enrolled
in two double-blind, randomized, placebo-controlled trials. The CFA was
conducted using maximum likelihood and weighted, least-squares factor extrac-
tion methods. The EFA was performed using a polychoric correlation covari-
ance matrix and Pearson correlation matrix. Results: Data from a pooled
population of 685 patients (venlafaxine ER: n = 339; placebo: n = 346) were
analyzed. CFA rejected the DSM-IV three-factor structure. The EFA identified a
different three-factor structure as the best fit: factor 1 included reexperiencing
symptoms, factor 2 included symptoms of altered mood and cognition, whereas
factor 3 comprised avoidance and arousal symptoms. All DSM-IV symptom
factors and all factors in the identified three-factor model responded positively
to venlafaxine ER treatment. Conclusions: Data are consistent with literature
failing to confirm the three-factor structure of DSM-IV PTSD, and they
support the DSM-5 inclusion of a symptom cluster addressing altered mood
and cognition in PTSD. The efficacy of venlafaxine ER in reducing a range of
symptom clusters in PTSD is consistent with its multiple mechanisms of action.
Introduction
Posttraumatic stress disorder (PTSD) is characterized by a
broad range of symptoms and behaviors stemming from
exposure to a traumatic event that is a perceived threat to
oneself or others. The PTSD symptoms described in the
Diagnostic and Statistical Manual of Mental Disorders
(Fourth Edition) (DSM-IV) (American Psychiatric Associ-
ation 1994) are divided into three clusters: reexperiencing,
avoidance/numbing, and hyperarousal. The validity of the
current conceptualization of PTSD described in DSM-IV
has been questioned because of the often heterogeneous
presentation of PTSD; the overlap in symptom criteria
between PTSD, other anxiety disorders, and major
depressive disorder; and the high comorbidity rate among
these disorders (North et al. 2009). A number of factor
analyses have been conducted, most suggesting alternative
two-, three-, or four-factor models of PTSD that provide
different conceptualizations of PTSD: including additional
symptom clusters such as dysphoria, or distinguishing
between an active avoidance and passive numbing factor
(Foa et al. 1995; Buckley et al. 1998; King et al. 1998;
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Asmundson et al. 2000; Amdur and Liberzon 2001;
Gaffney 2003; Baschnagel et al. 2005; Elhai et al. 2009).
Posttraumatic stress disorder factor analyses tradition-
ally have focused only on identifying symptoms that clus-
ter in a given population, while significantly less attention
has been paid to exploring how these factors respond to
treatment. Antidepressant pharmacotherapy has been shown
to be clinically efficacious for treating PTSD (Davidson
2006). However, inconsistencies in patterns of treatment
response, including variations in response rates (Stein
et al. 2009), have been observed in PTSD patients treated
with these agents. By assessing the relationship between
PTSD symptom clusters and response to pharmacother-
apy, we may further our ability to predict response to
treatment and possibly contribute to our understanding
of the way in which these treatments ameliorate PTSD
symptomatology. Analogous studies in other anxiety
disorders have been of value (Mataix-Cols et al. 1999;
Stein et al. 2006a, 2007).
This factor analysis was designed to investigate PTSD
symptom clusters pooled from patients who participated
in two randomized, placebo-controlled clinical trials that
demonstrated the efficacy of flexible doses of venlafaxine
extended release (ER) (37.5–300 mg/d) for the treatment
of PTSD (Davidson et al. 2006a,b). The venlafaxine ER
PTSD data set provides the opportunity to conduct a fac-
tor analysis using a large cross-national sample and to
assess how the identified symptom clusters respond to
treatment with venlafaxine ER. Our hope was that these
analyses would shed additional light not only on the gen-
eral question of the symptom structure of PTSD but also
on the more specific question of whether PTSD symptom
clusters are responsive to venlafaxine treatment.
Methods
Study design
Baseline and week 12 CAPS-SX17 data from two double-
blind, randomized, placebo-controlled trials that assessed
the efficacy of venlafaxine ER for the treatment of PTSD
were pooled for these factor analyses. The full methodol-
ogy and results of these studies have been published else-
where (Davidson et al. 2006a,b). The first was a 12-week
study, conducted in the US, that assessed the efficacy of
venlafaxine ER (37.5–300 mg/d) and sertraline (25–
200 mg/d), versus placebo for treating PTSD (Davidson
et al. 2006b). The second study was 24 weeks in duration
and conducted in 12 countries: Argentina, Chile, Colom-
bia, Denmark, Finland, Mexico, Norway, Portugal, South
Africa, Spain, Sweden, and the United Kingdom. It was
designed to compare the efficacy of venlafaxine ER (37.5–
300 mg/d) with placebo (Davidson et al. 2006a). For both
studies, the dosing schedule for venlafaxine ER was flexi-
ble and could be increased to a maximum of 75 mg/d at
day 5, 150 mg/d at day 14, 225 mg/d at day 28, and
300 mg/d at day 42. These studies were conducted in
accordance with the US Food and Drug Administration
Code of Federal Regulations (21CFR, Part 50), with the
ethical principles in the Declaration of Helsinki, and were
consistent with Good Clinical Practice and applicable reg-
ulatory requirements. They received independent ethics or
institutional review board approval in each country before
the study began, and written informed consent was
obtained from all patients prior to enrollment. For the
current factor analyses, only data from the venlafaxine ER
and placebo groups from this study were included.
Patients
Study participants were medically stable adult outpatients
with a primary diagnosis of PTSD according to DSM-IV
criteria, who had been experiencing symptoms for
≥6 months and had a baseline score of ≥60 on the 17-
item Clinician-Administered PTSD Scale (CAPS-SX17)
(Blake et al. 1995). Exclusion criteria included a current
primary diagnosis of major depression or an anxiety dis-
order other than PTSD; a current mental disorder due to
a general medical condition or history of bipolar disorder,
schizophrenia, or other psychotic disorder; alcohol or
drug abuse or dependence within 6 months of randomi-
zation or a positive urine drug screen; and a high risk of
suicide or violence. The baseline demographic characteris-
tics for the individual studies and the pooled population
are described in Table 1.
Outcomes
The CAPS-SX17 was the primary outcome measure for
both studies. The CAPS-SX17 is a rating scale based on
the 17 PTSD symptoms described in DSM-IV (Table 2),
which includes three clusters or subscales (i.e., reexperi-
encing, avoidance/numbing, and hyperarousal).
Statistical analysis
Factor analyses
These factor analyses were performed using baseline data
collected prior to treatment administration, which allowed
for the pooling of the venlafaxine ER and placebo treatment
arms of both studies. Additionally, separate analyses of each
individual study were conducted as a means of cross-vali-
dation. An initial confirmatory factor analysis (CFA) was
performed using the prespecified three-factor structure
described in the DSM-IV to determine whether the current
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data fit this structure. If the data did not fit, an exploratory
factor analysis (EFA) was planned to identify symptoms
that cluster in this population and to assess how these fac-
tors respond to treatment.
The CFA was performed using a maximum likelihood
factor extraction method for normally distributed data
and a weighted least-squares factor extraction method for
categorical data; two methods were used to see if similar
factors were extracted with both methods. These CFA
models used Hu and Bentler’s (1999) recommendation of
a combination of two goodness-of-fit indexes (Hu and
Bentler 1999). This combination included a noncentrali-
ty-based index such as a root mean square error of
approximation (RMSEA) to indicate the amount of unex-
plained variance with a criteria of <0.60, and a relative fit
index, such as Bentler–Bonett Non-normed Index that
has a penalty for adding parameters with a criteria of
>0.90 for acceptable fit.
The EFA was performed using a polychoric correlation
covariance matrix; a technique for estimating correlations
among theorized normally distributed continuous latent
variables from observed ordinal variables. A sensitivity
analysis was conducted that used the Pearson correlation
matrix. The maximum likelihood extraction method was
used to extract the factors, and an oblique, promax factor
rotation method was used to allow for correlated factors.
The maximum likelihood factor extraction method, which
provides statistical testing (i.e., goodness of fit for the
model, significance testing of factor loadings), is best for
relatively normally distributed data (Fabrigar et al. 1997).
The number of extracted factors to retain was determined
by examining scree plots of factors versus eigenvalues,
Horn’s parallel analysis, and the Schwarz’s Bayesian Crite-
ria (SBC) goodness-of-fit test (Fabrigar et al. 1999). To
determine whether an item belonged in a factor, the
lower limit of the 95% confidence interval (CI) for that
item was required to be greater than 0.30 in either study
individually or in the pooled study analysis.
Treatment effect analysis
The treatment effect analysis was conducted using adjusted
effect sizes from an analysis of covariance (ANCOVA)
model of change from baseline to week 12 using unit-
standardized CAPS-SX17 scores and unit-standardized, fac-
tor-transformed CAPS-SX17 scores. CAPS-SX17 scores were
standardized by dividing each mean score by the number
of items used to calculate the end point score, which
allowed the results to remain in the (0–8) units of the
original scale. These models were adjusted for baseline
CAPS-SX17 score and study protocol. Both last observation
carried forward (LOCF) and observed case analyses (OC)
Table 1. Baseline demographic characteristics.
Study 1 Study 2 Pooled
Venlafaxine
ER (n = 179)
Placebo
(n = 179)
Venlafaxine
ER (n = 161)
Placebo
(n = 168)
Venlafaxine
ER (n = 340)
Placebo
(n = 347)
Race, n (%)
White 121 (67.6) 135 (75.4) 92 (57.1) 100 (59.5) 213 (62.7) 235 (67.7)
Black 36 (20.1) 21 (11.7) 4 (2.5) 3 (1.8) 40 (11.8) 24 (6.9)
Hispanic 20 (11.2) 17 (9.5) 54 (33.5) 57 (33.9) 74 (21.8) 74 (21.3)
Asian 0 (0.0) 0 (0.0) 1 (0.6) 2 (1.2) 1 (0.3) 2 (0.6)
Other 2 (1.1) 6 (3.4) 10 (6.2) 6 (3.6) 12 (3.5) 12 (3.5)
Gender, n (%)
Female 124 (69.3) 114 (63.7) 89 (55.3) 89 (53.0) 213 (62.7) 203 (58.5)
Male 55 (30.7) 65 (36.3) 72 (44.7) 79 (47.0) 127 (37.4) 144 (41.5)
Type, n (%)
Accidental injury 18 (10.1) 21 (11.7) 30 (18.6) 31 (18.5) 48 (14.1) 52 (15.0)
Combat 19 (10.6) 18 (10.1) 20 (12.4) 20 (11.9) 39 (11.5) 38 (11.0)
Natural disaster 2 (1.1) 0 (0.0) 5 (3.1) 2 (1.2) 7 (2.1) 2 (0.6)
Nonsexual abuse 51 (28.5) 48 (26.8) 42 (26.1) 52 (30.1) 93 (27.4) 100 (28.8)
Sexual abuse (adult) 26 (14.5) 26 (14.5) 19 (11.8) 21 (12.5) 45 (13.2) 47 (13.5)
Sexual abuse (childhood) 28 (15.6) 28 (15.6) 2 (1.2) 1 (0.6) 30 (8.8) 29 (8.4)
Unexpected death 22 (12.3) 21 (11.7) 26 (16.2) 18 (10.7) 48 (14.1) 39 (11.2)
Unknown 3 (1.7) 2 (1.1) 0 (0.0) 1 (0.6) 3 (0.9) 3 (0.9)
Witnessing 7 (3.9) 11 (6.2) 11 (6.8) 13 (7.7) 18 (5.3) 24 (6.9)
Other 3 (1.7) 4 (2.2) 6 (3.7) 9 (5.4) 9 (2.7) 13 (3.8)
CAPS-SX17, mean (SD)
Total 84.0 (15.0) 81.6 (14.7) 81.0 (14.6) 82.9 (15.5) 82.6 (14.8) 82.2 (15.1)
CAPS-SX17, 17-item Clinician-Administered PTSD Scale; ER, extended release; PTSD, posttraumatic stress disorder.
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were performed. In addition to the ANCOVA analysis of
the change from baseline score on the unit-standardized
CAPS-SX17, three transformations were conducted on the
CAPS-SX17. The first created separate analyses of the origi-
nal unit-standardized CAPS-SX17 for each DSM-IV category
(i.e., reexperiencing, avoidance/numbing, and hyperarous-
al). The second set of transformations created separate
analyses for each of the three factors, by averaging only the
items that loaded significantly in each of the factors. The
third transformation represented factor-weighted adjust-
ments of CAPS-SX17, which was obtained by multiplying
factor scoring coefficients for each of the CAPS-SX17 items
before summation.
Results
Confirmatory factor analysis
The CFA demonstrated a significant lack of fit for the
DSM-IV three-factor PTSD symptom structure in the
pooled sample, as well as in the individual trials. The
RMSEA criteria (values of 0.05 and 0.06 vs. recommended
value <0.05), and Bentler–Bonett Normed Fit Index
(value of 0.58 and 0.74 vs. a recommended value of
>0.90) in the pooled sample suggested that the EFA was
warranted.
The polychoric correlation structure for the pooled
studies (Table 3), the scree plot with Horn’s parallel
analysis (Fig. 1), and SBC goodness-of-fit test from the
maximum likelihood factor analysis suggested a three-
factor structure. The SBC has the largest absolute value
and is the best fit for the three-factor structure (285),
with slightly smaller values for two- (236) and four-factor
(279) structures. The same analyses were performed with
the individual study data, as well as additional analyses
that used the pooled Pearson correlation matrix for nor-
mally distributed data, all of which produced results that
were similar to those described above.
Therefore, the EFA suggests a three-factor structure;
the first two factors loaded on the same items for both
studies and the third factor loaded on different items for
each study. Items with factors that loaded with a 95% CI
≥0.30 were considered to load highly and significantly on
the corresponding factor (Table 3). Factor 1 comprised
primarily reexperiencing symptoms, with the highest
loading symptoms for items 1 (intrusive recollections), 3
(acting or feeling as if events were recurring), 4 (distress
at exposure to trauma cues), and 5 (physiological reactiv-
ity on exposure to cues), and potentially item 2 (distress-
ing dreams) and 6 (avoidance of thoughts). Factor 2
mainly consisted of mood and cognitive symptoms,
including items 9 (diminished interest), 10 (detachment/
estrangement), and 11 (restricted range of affect) and
potentially 15 (difficulty concentrating), which loaded
highly in the international study but not the US study.
For the US study, factor 3 mainly consisted of hypera-
rousal symptoms: 16 (hypervigilance) and 17 (exaggerated
startle response). For the international study, factor 3
mainly consisted of avoidance symptoms: items 6 (avoid-
ance of thoughts, feelings, or conversations) and 7
(avoidance of activities, places, or people). In the rejected
four-factor model, arousal and avoidance separated into
two different factors. Based on the present data, items 8
(inability to recall important aspect of trauma), 12 (sense
of foreshortened future), 13 (difficulty with sleep), and 14
(irritability or outbursts of anger) did not meet the
criteria for clear inclusion in any factor.
Treatment effect analysis
After 12 weeks of treatment with venlafaxine ER or
placebo, the original analyses produced an adjusted effect
size for the mean treatment difference of 0.32
(P < 0.001 vs. placebo; LOCF analysis) (Table 4). Analysis
of individual DSM-IV symptom categories (i.e.,
reexperiencing, avoidance/numbing, or hyperarousal) also
produced significant treatment effects: –0.25 (P = 0.002),
–0.30 (P < 0.001), and –0.28 (P = 0.001), respectively
(Table 5). The three new groupings based on the EFA
(reexperiencing [items 1–5]; altered mood/cognition
[items 9, 10, 11, and 15]; and avoidance/arousal [items 6,
Table 2. DSM-IV/CAPS-SX17 PTSD symptom clusters (the prespecified
three-factor structure).
Reexperiencing Item 1: Intrusive recollections
Item 2: Distressing dreams
Item 3: Feeling events were recurring
Item 4: Distress at exposure to cues
Item 5: Reactivity on exposure to cues
Avoidance/Numbing Item 6: Avoidance of thoughts, feelings,
or conversations
Item 7: Avoidance of activities, places,
or people
Item 8: Inability to recall important aspects
of trauma
Item 9: Diminished interest or participation
in activities
Item 10: Detachment or estrangement
Item 11: Restricted range of affect
Item 12: Sense of a foreshortened future
Hyperarousal Item 13: Difficulty falling or staying asleep
Item 14: Irritability or outbursts of anger
Item 15: Difficulty concentrating
Item 16: Hypervigilance
Item 17: Exaggerated startle response
CAPS-SX17, 17-item Clinician-Administered PTSD Scale; DSM-IV, Diag-
nostic and Statistical Manual of Mental Disorders (Fourth Edition);
PTSD, posttraumatic stress disorder.
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7, 16, and 17]) produced comparable results: 0.25
(P = 0.002), 0.28 (P < 0.001), and 0.25 (P = 0.001),
respectively (Table 6). Compared with unweighted
item sums for the suggested factors, factor-weighted
adjustment produced a greater effect size (factor 1, 0.27
vs. 0.25; factor 2, 0.30 vs. 0.28; and factor 3, 0.29
vs. 0.25; Tables 6 and 7). Results from the OC analyses
were similar.
Discussion
Although the DSM-IV conceptualizes PTSD in terms of
three symptom clusters, a large and diverse body of data
exists suggesting other possible PTSD symptom structures.
The most common are four-factor models, although these
often include reexperiencing, avoidance, and arousal symp-
tom clusters (Asmundson et al. 2000; Amdur and Liberzon
Table 3. Factor analysis rotated factor loading for three factors from EFA of polychoric correlation matrix with ML factor extraction and oblique
(promax) rotation methods.
CAPS-SX17 item
Factor 1 Factor 2 Factor 3
US Int’l Pooled US Int’l Pooled US Int’l Pooled
Reexperiencing 1. Intrusive recollections 0.75* 0.62* 0.70* 0.21 0.14 0.20 0.04 0.13 0.00
2. Distressing dreams 0.34 0.38** 0.37* 0.15 0.02 0.10 0.24 0.10 0.13
3. Feeling events recurring 0.47* 0.53* 0.53* 0.06 0.16 0.07 0.09 0.04 0.06
4. Distress at exposure to cues 0.65* 0.70* 0.67* 0.08 0.13 0.08 0.12 0.03 0.13
5. Reactivity on exposure to cues 0.50* 0.71* 0.58* 0.02 0.10 0.02 0.22 0.03 0.20
Avoidance/
Numbing
6. Avoidance of thoughts 0.37** 0.32 0.34** 0.22 0.16 0.22 0.27 0.53* 0.31
7. Avoidance of activities 0.22 0.25 0.22 0.23 0.22 0.26 0.35 0.67* 0.39**
8. Inability to recall trauma 0.02 0.05 0.01 0.07 0.01 0.07 0.18 0.19 0.14
9. Diminished interest 0.07 0.18 0.11 0.63** 0.67* 0.64* 0.23 0.04 0.17
10. Detachment/estrangement 0.07 0.11 0.06 0.77* 0.66* 0.75* 0.07 0.13 0.12
11. Restricted range of affect 0.08 0.06 0.07 0.68* 0.65* 0.66* 0.06 0.07 0.12
12. Sense of foreshortened future 0.22 0.30 0.26 0.24 0.37 0.20 0.18 0.07 0.21
Hyperarousal 13. Difficulty falling/staying asleep 0.13 0.29 0.16 0.30 0.19 0.29 0.32 0.08 0.22
14. Irritability/outbursts of anger 0.18 0.29 0.20 0.24 0.24 0.20 0.19 0.08 0.26
15. Difficulty concentrating 0.22 0.08 0.14 0.33 0.46* 0.39* 0.07 0.12 0.12
16. Hypervigilance 0.06 0.19 0.08 0.09 0.29 0.14 0.54* 0.22 0.54*
17. Exaggerated startle response 0.24 0.29 0.27 0.03 0.22 0.01 0.59* 0.33 0.54*
CAPS-SX17, 17-item Clinician-Administered PTSD Scale; EFA, exploratory factor analysis; Int’l, international; ML, maximum likelihood; PTSD, post-
traumatic stress disorder.
*Lower 95% confidence limit ≥0.30.
**Lower 95% confidence limit ≥0.25.
Figure 1. Scree plot of eigenvalues (from
reduced correlation matrix) by number of
factors. Parallel Analysis – Median
Simulated Eigenvalues (17 variables, 1000
iterations, and 860 observations).
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Table 4. Treatment effect on original CAP-SX17
*, averaged over all items, and each of the original three groupings (LOCF analysis).
Population
Treatment group
(n at baseline/week 12)
Baseline,
mean (SD)
Week 12,
mean (SD)
Adjusted
mean change** (SD)
Adjusted
effect size**
(adjusted mean
chg/SD) P-value**
Pooled studies Venlafaxine ER (n = 339/324) 4.9 (0.9) 2.2 (1.7) 2.6 (0.1) 0.315 <0.001
Placebo (n = 346/332) 4.8 (0.9) 2.7 (1.7) 2.1 (0.1)
Study 735 Venlafaxine ER (n = 179/171) 4.9 (0.9) 2.5 (1.8) 2.5 (0.1) 0.265 0.015
Placebo (n = 179/170) 4.8 (0.9) 2.8 (1.8) 2.0 (0.1)
Study 786 Venlafaxine ER (n = 160/153) 4.8 (0.9) 2.0 (1.5) 2.8 (0.1) 0.397 <0.001
Placebo (n = 167/162) 4.9 (0.9) 2.6 (1.7) 2.2 (0.1)
ANCOVA, analysis of covariance; CAPS-SX17, 17-item Clinician-Administered PTSD Scale; ER, extended release; LOCF, last observation carried for-
ward; PTSD, posttraumatic stress disorder; SD, standard deviation.
*CAPS-SX17 = (item 1 + ··· + item 17)/17.
**From ANCOVA model: CAPS-SX17 chg = baseline CAPS-SX17 + treatment + pooled site.
Table 5. Treatment effect on each of the original three groupings for CAP-SX17, averaged over items in category (pooled and LOCF analysis).
Factor
number DSM-IV category
Treatment group
(n at baseline/week 12)
Baseline,
mean (SD)
Week 12,
mean (SD)
Adjusted
mean change* (SD)
Adjusted
effect size*
(adjusted mean
chg/SD) P-value*
1 Reexperiencing
(items 1–5)
Venlafaxine ER (n = 339/324) 4.8 (1.3) 2.0 (1.9) 2.9 (0.1) 0.249 0.002
Placebo (n = 346/332) 4.7 (1.4) 2.4 (2.0) 2.3 (0.1)
2 Avoidance/Numbing
(items 6–12)
Venlafaxine ER (n = 339/324) 4.7 (1.2) 2.2 (1.9) 2.6 (0.1) 0.295 <0.001
Placebo (n = 346/332) 4.8 (1.1) 2.7 (1.9) 2.1 (0.1)
3 Hyperarousal
(items 13–17)
Venlafaxine ER (n = 339/324) 5.1 (1.1) 2.6 (1.9) 2.5 (0.1) 0.284 <0.001
Placebo (n = 346/332) 5.0 (1.2) 3.0 (1.9) 2.0 (0.1)
ANCOVA, analysis of covariance; CAPS-SX17, 17-item Clinician-Administered PTSD Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Dis-
orders (Fourth Edition); ER, extended release; LOCF, last observation carried forward; PTSD, posttraumatic stress disorder; SD, standard deviation.
Factor 1-summed CAPS-SX17 = (item 1 + item 2 + item 3 + item 4 + item 5)/5.
Factor 2-summed CAPS-SX17 = (item 6 + item 7 + item 8 + item 9 + item 10 + item 11 + item 12)/7.
Factor 3-summed CAPS-SX17 = (item 13 + item 14 + item 15 + item 16 + item 17)/5.
*From ANCOVA model: CAPS-SX17 chg = baseline CAPS-SX17 + treatment + pooled site.
Table 6. Treatment effect on each of the three new factor-summed CAP-SX17, averaged over items in category* (pooled and LOCF analysis).
Factor
number New category
Treatment group
(n at baseline/week 12)
Baseline,
mean (SD)
Week 12,
mean (SD)
Adjusted
mean change**
(SD)
Adjusted
effect size**
(adjusted mean
chg/SD) P-value**
1 Reexperiencing
(items 1–5)
Venlafaxine ER (n = 339/324) 4.8 (1.3) 2.0 (1.9) 2.8 (0.1) 0.249 0.002
Placebo (n = 346/332) 4.7 (1.4) 2.4 (2.0) 2.3 (0.1)
2 Altered mood/Cognition
(items 9, 10, 11, and 15)
Venlafaxine ER (n = 339/324) 5.3 (1.3) 2.5 (2.2) 2.8 (0.1) 0.277 <0.001
Placebo (n = 346/332) 5.2 (1.3) 3.0 (2.3) 2.2 (0.1)
3 Avoidance/Arousal
(items 6, 7, 16, and 17)
Venlafaxine ER (n = 339/324) 4.9 (1.4) 2.4 (2.0) 2.6 (0.1) 0.252 0.001
Placebo (n = 346/332) 5.0 (1.4) 2.8 (2.1) 2.1 (0.1)
ANCOVA, analysis of covariance; CAPS-SX17, 17-item Clinician-Administered PTSD Scale; ER, extended release; LOCF, last observation carried for-
ward; PTSD, posttraumatic stress disorder; SD, standard deviation.
Factor 1-summed CAPS-SX17 = (item 1 + item 2 + item 3 + item 4 + item 5)/5.
Factor 2-summed CAPS-SX17 = (item 9 + item 10 + item 11 + item 15)/4.
Factor 3-summed CAPS-SX17 = (item 6 + item 7 + item 16 + item 17)/4.
*Each factor-summed CAPS-SX17 category is based on significant factor loadings.
**From ANCOVA model: CAPS-SX17 chg = baseline CAPS-SX17 + treatment + pooled site.
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2001; Baschnagel et al. 2005; McWilliams et al. 2005).
Fewer three-factor models have been reported; however,
Foa et al. (1995) performed a principal components factor
analysis of assault victims that yielded a three-factor struc-
ture: arousal/avoidance, numbing, and intrusion. In line
with the majority of the data, a four-factor symptom struc-
ture is incorporated into the DSM-5 diagnostic criteria for
PTSD: (1) reexperiencing, (2) avoidance, (3) arousal and
reactivity, and (4) negative alterations in mood and cogni-
tion (Friedman et al. 2011). This analyses are at least par-
tially supportive of this approach, having revealed
symptom clusters that include reexperiencing, altered
mood and cognition, and avoidance/arousal (with avoid-
ance in the international study and arousal in the US
study). For both the three-factor DSM-IV and three-factor
EFA models of PTSD symptom structures, the current
analyses in a large, pooled group of patients with PTSD
demonstrated a significantly greater response to venlafaxine
versus placebo on all symptom clusters.
Across studies, including factor analyses, conducted in
patients with PTSD, there is diversity in the type of popu-
lations studied (e.g., male veterans, female psychiatric
outpatients), types of trauma (e.g., automobile accidents,
rape, exposure to combat), and the assessment tools used
(e.g., CAPS-SX17, Impact of Event Scale [Horowitz et al.
1979]). It is notable that even within the pooled popula-
tion assessed here, differences in trauma type were
observed between the two studies. Specifically, in the
internationally conducted study, the incidence of child-
hood sexual abuse (1%) (Davidson et al. 2006a) was
lower than that in the US study (15%) (Davidson et al.
2006b), which may be attributable to cultural variations
associated with discussing traumatic events. The diversity
of PTSD patients is a primary limitation of this and other
conducted studies. In addition, the criteria used to select
a study population for a clinical trial, which generally
exclude patients with comorbid psychiatric and substance
use disorders, may have created a population that is not
representative of PTSD patients in the general population.
The often heterogeneous response to antidepressant
pharmacotherapy has led to a questioning of the efficacy of
such agents for treating PTSD. The review conducted by
the National Institute for Health and Clinical Excellence in
the United Kingdom used an a priori definition of clinical
significance as an effect size of 0.5, and found that few trials
met this threshold (National Institute for Clinical Excel-
lence 2005). Similarly, an Institute of Medicine report,
which reviewed available treatments for PTSD, suggested
that the data from studies assessing the efficacy of pharma-
cotherapy are inadequate to demonstrate consistent effi-
cacy. The report argued that the characteristics of and
variability among industry-sponsored clinical trials—which
use study populations that exclude certain patient types
(e.g., substance abusers), have high rates of attrition, and
have different methods for addressing missing data—make
it hard to generalize their results to the larger patient popu-
lation (Committee on Treatment of Posttraumatic Stress
Disorder 2008). On the other hand, the Cochrane meta-
analysis of PTSD treatments found that pharmacotherapy,
in particular the selective serotonin reuptake inhibitors,
produces clinically and statistically significant improve-
ments in PTSD symptomatology (Stein et al. 2006b). The
serotonin–norepinephrine reuptake inhibitor, venlafaxine
ER, also has empirically demonstrated efficacy in exerting a
statistically and clinically significant treatment response in
the primary published studies of these data sets (Davidson
et al. 2006a,b) and in a subsequent CAPS-SX17 individual
item analysis (Stein et al. 2009), and the data here provide
additional information on the efficacy of this agent.
One possible explanation of the observed variability in
treatment outcomes in PTSD patients is that there are
different psychobiological mechanisms that mediate dif-
ferent symptoms. Theories that seek to explain the neuro-
biological processes underlying PTSD symptomatology
Table 7. Treatment effect on each of the new factor-weighted CAP-SX17, averaged over all items* (pooled and LOCF analysis).
Factor
number
Treatment group
(n at baseline/week 12)
Baseline,
mean (SD)
Week 12,
mean (SD)
Adjusted mean
change (SD)
Adjusted
effect size
(adjusted
mean chg/SD) P-value**
1 Venlafaxine ER (n = 339/324) 7.1 (1.5) 3.1 (2.6) 4.0 (0.1) 0.267 <0.001
Placebo (n = 346/332) 7.1 (1.6) 3.7 (2.7) 3.4 (0.1)
2 Venlafaxine ER (n = 339/324) 7.0 (1.6) 3.3 (2.8) 3.7 (0.1) 0.296 <0.001
Placebo (n = 346/332) 6.9 (1.6) 4.0 (2.8) 2.9 (0.1)
3 Venlafaxine ER (n = 339/324) 6.6 (1.7) 3.2 (2.5) 3.5 (0.1) 0.290 <0.001
Placebo (n = 346/332) 6.7 (1.6) 3.9 (2.6) 2.8 (0.1)
CAPS-SX17, 17-item Clinician-Administered PTSD Scale; ER, extended release; SD, standard deviation.
*Each factor-weighted CAPS-SX17 is calculated by using the factor scoring coefficients as weights on each of the CAPS-SX17 item values. Then it
is averaged over all items by dividing by 17.
**Analysis of covariance.
744 ª 2013 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
PTSD Symptom Factors and Treatment Response D. J. Stein et al.
have suggested that noradrenergic hyperactivity plays a
significant role. Specifically, innervations of noradrenaline
from the locus coeruleus to the amygdala, prefrontal
cortex, and hippocampus have been linked to the devel-
opment of conditioned fear responses, which can produce
chronic hyperarousal, reexperiencing symptoms, and, in
turn, may lead to avoidance behaviors and emotional
numbing (Charney et al. 1993). At the same time, seroto-
nin may also play a key role in PTSD, either directly or
indirectly, by regulating the activity of noradrenaline
(Newport and Nemeroff 2000). Venlafaxine ER blocks the
reuptake of both noradrenaline (norepinephrine) and
serotonin, which may explain the observed improvements
in a range of different symptom clusters. Future research
should seek to further clarify the relationship between the
neurochemical correlates of PTSD symptomatology by
assessing the effect of available treatment options, possibly
those with different mechanisms of action, on identified
symptom clusters. Performing such analyses may further
the understanding of PTSD and lead to improvements in
the treatment options available to patients.
This analysis has a number of strengths, including a large
and diverse sample size and data pooled from patients trea-
ted in a randomized, double-blind design. However, it is
important to emphasize a number of limitations. First, as
noted above, patients who are enrolled in clinical trials dif-
fer from the general population of PTSD patients in impor-
tant ways, and within each trial there may be further
particularities, such as the set of traumas to which subjects
were exposed. Second, there was insufficient power to ana-
lyze the response of symptom clusters to sertraline treat-
ment (a sertraline arm was included in only one of the
studies). Third, because no actual assessment of neuro-
transmitter activity was conducted, any explanation of how
these results relate to the mechanism of action of venlafax-
ine ER is speculative. Despite these limitations and the pre-
liminary nature of these analyses, the results of the current
factor analysis, in the context of the treatment response
analysis, support the efficacy of venlafaxine ER for improv-
ing all PTSD symptom clusters that are relevant to this
patient population. Additional work is needed to confirm
the factor structure found here in more representative sam-
ples, to determine the underlying psychobiological mecha-
nisms of PTSD symptom factors, and to determine whether
these have a differential treatment response.
Conclusions
This factor analysis of PTSD symptoms suggests an alter-
nate three-factor model that differs from the three-factor
model described in the DSM-IV. The data here are
consistent with a literature that has failed to confirm the
three-factor structure of DSM-IV PTSD, and that has sug-
gested that key symptom clusters in PTSD are reexperi-
encing, avoidance, arousal, and negative changes in mood
and cognition. Furthermore, these analyses provide addi-
tional support for the efficacy of venlafaxine ER for treat-
ing PTSD by demonstrating a significant treatment effect
on the symptoms in the DSM-IV three-factor model and
the newly identified three-factor model.
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